14 mayo 2015
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care – invasive surgery – according to research from a phase III randomized international study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/nwEVOxMzpzU/150513210000.htm
